Guggenheim analyst Charles Zhu raised the firm’s price target on Zymeworks to $16 from $15 and keeps a Buy rating on the shares. The analyst said that full ASCO GI data continues to look "great," even prior to layering on PD-1. Zhu noted that, if he had to nitpick, the headline mDOR for zani + CAPOX was 10.4 months.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZYME:
- Jazz Pharmaceuticals, Zymeworks report 84% survival for zanidatamab in mGEA
- This Insider Just Spiked Investors’ Interest in Zymeworks (NASDAQ:ZYME) Stock
- Zymeworks up 4% afterhours as holder EcoR1 Capital buys $9.7M in common stock
- Zymeworks (NASDAQ:ZYME) Stock: Insider Buys Shares Worth $8M
- Zymeworks jumps 2% after holder EcoR1 Capital buys $8M in shares